Page last updated: 2024-08-23
5'-palmitoyl cytarabine and Myelodysplastic Syndromes
5'-palmitoyl cytarabine has been researched along with Myelodysplastic Syndromes in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Kimura, K; Ohno, R | 1 |
Other Studies
1 other study(ies) available for 5'-palmitoyl cytarabine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
[Treatment of myelodysplastic syndromes (MDS) with oral administration of N4-palmitoyl-1-beta-D-arabinofuranosyl cytosine (PLAC)].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Cytarabine; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Nausea | 1988 |